Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T13:58:16.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    A banner announces an NIH-wide terminology transition, saying that agencies are using “Super Intelligence” in place of “Artificial Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T14:52:48.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-19T14:44:12.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The site footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-12T14:47:53.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study content, signaling restricted access to this ClinicalTrials.gov record. The additions reflect the error page structure (doctype, meta, 403 title) and footer information showing the site revision.
    Difference
    19%
    Check dated 2026-09-21T22:17:35.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The page revision was updated to v3.6.6, indicating a small platform-level update. It does not change trial details, eligibility criteria, outcomes, or other substantive content on the study page.
    Difference
    0.1%
    Check dated 2026-08-31T18:28:45.000Z thumbnail image

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.